Thursday, 19 Jul 2018

You are here

RheumNow Week in Review – 22 July 2016

Highlights from this week on RheumNow.com include:

  1. In Tofacitinib developmental trials in RA and Psoriasis, there were 1821 women of child-bearing age who were exposed; 47 became pregnant (33 monoRx). There were no deaths and one congenital malformation (1 Pulmonic valve stenosis), 7 Spontaneous Abortions. http://buff.ly/2azDHwd
  2. BMS has a new autoinjector for abatacept (ORENCIA) called "ClickJect" with a 15 sec delivery duration https://t.co/6QHIqK51Pj
  3. Between 10-50% of colorectal cancer patients have a positive ANA by either EIA or IIF. Small study but instructive. https://t.co/WWMbH3J4Vw
  4. Pirfenidone is FDA approved for IPF. Open label study 63 PSS patients with IPF show it tolerable and safe but no effect on outcomes https://t.co/j2ujvmfMnF
  5. NEJM article by Drs. Taurog & Colbert review ankylosing spondylitis & Spondyloarthritis. https://t.co/L6lQSi9Gyn
  6. RWCS Pearl: Dapsone can be of benefit in SCLE patients who do not respond to antimalarials. https://t.co/5cOXVH42Xi
  7. WEGENT compared outcomes in 112 GPA & MPA patients; Imuran & MTX had similar 10 yr survival, relapse rates, & toxicities https://t.co/dIl4wnsRzY
  8. Adherence to T2T in 198 early RA pts had no effect on Xrays or 12 mos DAS, but significantly improved DAS & functional outcomes at 3 yrs. https://t.co/XrXhnEkkUl
  9. MTX in Psoriatic arthritis achieves MDA – minimal disease activity criteria in <20%. MDA defined as 5 or more of the following 7 criteria: SJC, PASI, entheses≤1, BSA≤3%, HAQ≤0.5, pt global≤20, Pt pain≤15. https://t.co/dO6qyys8yy
  10. Epigenetic Changes to Inflammasome Found in Autoinflammatory Syndromes. 
  11. DEXA Still Needed While on Bisphosphonates: a study of 6629 Canadian women with osteoporosis taking bisphosphonates finds ~20% have decrease in bone density on medication
  12. Prevalence of Spondyloarthropathy in Fibromyalgia. Sacroiliitis found in 8% of 99 FM patients. Axial SpA found in 10%. Inflammatory MRI imaging changes found in 17% to 25% of patients. 
  13. Will Patent Extensions Delay Biosimilar Arrivals
Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Proposed Changes for 2019 Medicare Fee Schedule

On July 12th the Centers for Medicare & Medicaid Services (CMS) released its proposed rule changes for the 2019 Medicare physician fee schedule.  This year, CMS has combined the Medicare physician fee schedule proposed rule with recommendations for the Quality Payment Program (QPP), which will be officially published in the Federal Register on July 27.

Trend Towards Fewer Self-Employed Physicians

 

A nationwide survey study analyzed healthcare provider (HCP) employment type (self-employed, employed by private sector, or employed by government) and annual labor earnings (2001 to 2015) and found that the health care landscape is changing with few self-employed practitioners and more being larger organizations. 

The RheumNow Week in Review –Fateful Outcomes in Rheumatology (7.13.18)

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.  Fateful outcomes in Rheumatology, what happens to Seronegatives, IL-23 fails, MRI progression, Not all inflammatory back pain becomes SpA:

The RheumNow Week in Review – Life Savers for Rheumatologists (6.29.18)

Dr. Jack Cush reviews selected news and journal reports from the past week on RheumNow.com.

The RheumNow Week in Review – EULAR18 Epilogue (6.22.18)

Dr. Jack Cush reviews EULAR 2018 and the past week's news and reports from RheumNow.com, including DMARDs in OA, the price of Penicillamine, Infections when ANCA+, CV outcomes in gout, NSAIDs in Pregnancy and Seropostive vs. Seronegative Outcomes.